Rivulet Media Inc (fka RIVU)

[Jleetx]

As I sit on my computer performing DD on BMSN, a smile is brought to my face as I see the recent PR release on the Middle East, North Africa Financial Network (menofn.com) as well as bioportfolio.com and naturalnews.com. This doesn't include the other main news outlets that are already discussed on this board about the profound arrangement with Benitec.

#1 fan here... Gene silencing is golden! Period. With this recent press release about the involvement with Benitec, it solidifies my investment and brings a new level of awareness on just how life changing this is from a potential cure and treatment perspective. This cutting edge science has global marketability and continues to receive praises and has the world in discussion about the break through in this science for a host of diseases. The breast cancer concentration that BMSN is targeting first hits home for me as my Mom struggled with chemo and has many side affects from this disease process. Luckily, we still have her here. The option for a non toxic approach is beneficial, natural, and great science. Is this the new wave of the future for cures? Absolutely. This is ground floor, cutting edge science at it's finest and we are lucky to arrive with a financial investment that can help pave the way to cures and financial freedom. I strongly belive this.

How ddRNAi is unique:(from Benitec)

In summary, in comparison to other gene silencing methods, the advantages of ddRNAi are:

Less fragile: construct is based on DNA not RNA, so is more robust and less easily degraded

Easier delivery: established, well-characterized gene therapy vectors can be used

Higher efficiency: up to 250 times compared to siRNA, and up to 1000 times compared to antisense, enabling significantly smaller doses to be used

Persistence: for up to years compared to hours or days, due to genetic change in the nucleus not transient change in the cytoplasm

Single or few doses: no need for ongoing administration

Lower toxicity: due to lower dose, short term administration

Lower immune activation: due to lower dose, short term administration

Fewer off-target effects: due to lower dose, short term administration

Wider application: many genes or many parts of one gene can be targeted with one dose. Can be administered ex vivo, or injected locally or systemically.

Global application: the ddRNAi platform can be licensed for many disease programs.

This is what I really like (read below): Benitec has years of progress in the works and they have found a perfect partner in BMSN. After you read this article, you will quickly see how crucial and exciting this news is for BMSN. This could be the most important science of this decade.

http://www.abc.net.au/catalyst/stories/s799730.htm

This article is from June 2003 and it highlights Benitec. For the impatient, you need to see the amount of work that has occurred over the last 10 years to even get to this point of research and all the preparation for the FDA to consider this as an option.

Be thrilled that you are here and that you own a position in this technology by being associated with BMSN.

Another item, BMSN doesnt just have a one shot science application to market. They have numerous opportunities for a host of diseases with this technology. Also, not to mention an orphan designation that will come to fruition in due time. And, my friends, this is just at the infancy stage. It will receive a hightened global awareness that will be stronger as the trials progress with favorabole data to support life changing outcomes.

Also, in your spare time, my advice is to join some discussion groups on Aplastic Anemia chat rooms. They see a lot of hope in Hemaxellerate and can't wait. The buzz is definitely getting around.

Stay patient and positive. I enjoy the interaction and reading the posts on a daily basis. I would also like to challenge the baord to remain professional and on topic. I have been guilty myself of not following my own advice. Love your neighbor and be kind. Life's too short.

Good luck to all.